Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,542,253
  • Shares Outstanding, K 104,259
  • Annual Sales, $ 87,990 K
  • Annual Income, $ -84,550 K
  • 60-Month Beta 1.23
  • Price/Sales 73.89
  • Price/Cash Flow N/A
  • Price/Book 16.09
Trade ARWR with:

Options Overview Details

View History
  • Implied Volatility 59.87%
  • Historical Volatility 29.43%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 89.55% on 03/05/21
  • IV Low 59.87% on 09/22/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 181
  • Volume Avg (30-Day) 558
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 7,051
  • Open Int (30-Day) 11,953

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.04
  • Number of Estimates 6
  • High Estimate 1.73
  • Low Estimate -0.43
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +108.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.55 +3.63%
on 08/23/21
69.65 -9.91%
on 09/02/21
+2.82 (+4.71%)
since 08/20/21
3-Month
57.92 +8.34%
on 08/11/21
93.66 -33.00%
on 06/23/21
-26.08 (-29.36%)
since 06/22/21
52-Week
42.40 +48.00%
on 09/28/20
93.66 -33.00%
on 06/23/21
+18.95 (+43.26%)
since 09/22/20

Most Recent Stories

More News
RNAi Technology Market Size, Share, Value, Competitive landscape, Industry outlook and Future Forecast till 2027

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy...

ALNY : 182.21 (-1.05%)
DRNA : 20.10 (-2.80%)
ARWR : 62.75 (+0.63%)
IONS : 36.56 (+0.77%)
ABUS : 4.44 (+1.60%)
BLT : 10.00 (+0.20%)
SLN.LN : 533.200 (+0.60%)
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2021. The company is hosting a conference call today, August 5, 2021, at 4:30...

ARWR : 62.75 (+0.63%)
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up

Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.

VRTX : 184.27 (-0.82%)
HZNP : 109.96 (+0.18%)
RGEN : 313.10 (-0.34%)
ARWR : 62.75 (+0.63%)
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for ARO-AAT, also known as TAK-999,...

ARWR : 62.75 (+0.63%)
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2021, the Compensation Committee of the Company's Board of...

ARWR : 62.75 (+0.63%)
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter...

ARWR : 62.75 (+0.63%)
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company's investigational...

ARWR : 62.75 (+0.63%)
Alector, Virgin Galactic rise; Arrowhead, Boeing fall

Stocks that traded heavily or had substantial price changes Friday:

TSLA : 751.94 (+1.70%)
ARWR : 62.75 (+0.63%)
ALEC : 25.00 (-4.47%)
C : 68.24 (+1.94%)
BA : 216.98 (+4.06%)
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase...

ARWR : 62.75 (+0.63%)
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROANG3-2001, a Phase 2b clinical study of ARO-ANG3, the company's investigational RNA interference...

ARWR : 62.75 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 64.51
2nd Resistance Point 63.81
1st Resistance Point 63.28
Last Price 62.75
1st Support Level 62.06
2nd Support Level 61.36
3rd Support Level 60.83

See More

52-Week High 93.66
Fibonacci 61.8% 74.08
Fibonacci 50% 68.03
Last Price 62.75
Fibonacci 38.2% 61.98
52-Week Low 42.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar